Open Orphan’s (ORPH) Maurice Treacy Hosts Value the Markets Webinar

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, announces that the Company’s Chief Commercial Officer, Maurice Treacy, will be hosting a webinar alongside Value the Markets on Wednesday 30th October 2019 at 19:00 (UK time). Maurice Treacy will take the opportunity to update existing and potential shareholders on Open Orphan and will provide an insight on the […]

Open Orphan plc (ORPH) Investor Event Attendance and Presentation

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at The London Investor Show at Novotel London West, London, W6 8DR this Friday 25th October 2019. Maurice Treacy, Open Orphan’s Chief Commercial Officer, will be in attendance and will be presenting in Conference […]

Open Orphan #ORPH signs strategic collaboration agreement with Empiric Logic

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed a new strategic collaboration agreement (“the Collaboration”) with Empiric Logic to build on the earlier work performed by Open Orphan and complete the build out of Open Orphan’s Health Data platform, Europe’s first rare disease, advocacy-led genomic database. Empiric […]

Open Orphan #ORPH presents at Shares Investor Evening, Manchester

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending and presenting at Shares Investor Evening at Macdonald Manchester Hotel, Manchester, M1 2PG from 18:00 on Thursday 10th October. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance and will be presenting to update existing and potential investors on […]

Open Orphan #ORPH – Interim Results for 6 months ended 30 June 2019

Open Orphan, a European-focused, rare and orphan drug consulting services platform, announces its interim results for the six months ended 30 June 2019. Financial Highlights below (and in note 3 of the reported financial statements) reflect the interim results of Venn Life Sciences (“Venn”) prior to the reverse takeover by Open Orphan on the 28 June […]

Open Orphan #ORPH presents at Total Market Solutions & Proactive Investors’ One2One Forum, London

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that on Wednesday 18th September the Company will be attending and presenting at Total Market Solutions, Moorgate, at 12:30pm and will also be attending and presenting at Proactive Investors’ One2One Forum at Chesterfield Mayfair Hotel, London, W1J 5EB from 18:00 onwards. Cathal Friel, Open Orphan’s Chief Executive Officer, will be in […]

Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year

https://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year Open Orphan (ORPH) CEO Cathal Friel tells Alan Green why he expects 40 percent growth year on year. Open Orphan (ORPH) currently trades on just 1x revenues & a market cap of just £15m. CEO Cathal Friel tells Alan Green why he expects to see his company, into which he’s invested £2m of his […]